Literature DB >> 25721141

Minilaparoscopic aortic lymphadenectomy.

Valerio Gallotta1, Camilla Nero2, Vito Chiantera3, Giovanni Scambia2.   

Abstract

STUDY
OBJECTIVE: To show the feasibility of performing aortic lymphadenectomy with 3-mm instruments in gynecologic malignancies. PATIENT: A 43-year-old, multiparous patient with serous ovarian cancer grading 2, Fédération Internationale de Gynécologie et d'Obstétrique stage IC (intraoperative spillage). INTERVENTION: The patient was accidentally diagnosed with ovarian cancer after a right adnexectomy performed for an ovarian cyst. Once referred to our center, a delayed surgical staging was planned including total hysterectomy, left adnexectomy, aortic and pelvic lymphadenectomy, peritoneal biopsies, and total omentectomy. Minilaparoscopy was believed to be feasible to achieve it.
MEASUREMENTS AND MAIN RESULTS: The operation was performed successfully with no intraoperative or postoperative complication. Operative time was 150 minutes overall, and blood loss was 50 mL. Twenty-three aortic lymph nodes were removed. The pathology report came back clean. The patient was discharged on day 1 and 10 days later started adjuvant chemotherapy. After 16 months, no recurrence was detected.
CONCLUSION: Minilaparoscopy aortic lymphadenectomy is technically feasible when performed by trained surgeons.
Copyright © 2015 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aortic lymphadenectomy; Gynecologic cancer; Minilaparoscopy

Mesh:

Year:  2015        PMID: 25721141     DOI: 10.1016/j.jmig.2015.02.011

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  1 in total

1.  Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage I-II High-Risk Endometrial Cancer.

Authors:  E Sun Paik; Seung Hun Baek; Jun Hyeok Kang; Soo Young Jeong; Myeong Seon Kim; Woo Young Kim; Yoo-Young Lee; Chel Hun Choi; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Tae-Joong Kim
Journal:  Front Oncol       Date:  2020-04-07       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.